Gemogenovatucel-T Immunotherapy as Maintenance in Frontline Stage III/IV Ovarian Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Gemogenovatucel-T (Vigil) Immunotherapy as Maintenance in Frontline Stage III/IV Ovarian Cancer (VITAL): A Randomised, Double-Blind, Placebo-Controlled, Phase 2b Trial
Lancet Oncol 2020 Dec 01;21(12)1661-1672, RP Rocconi, EA Grosen, SA Ghamande, JK Chan, MA Barve, J Oh, D Tewari, PC Morris, EE Stevens, JN Bottsford-Miller, M Tang, P Aaron, L Stanbery, S Horvath, G Wallraven, E Bognar, L Manning, J Nemunaitis, D Shanahan, BM Slomovitz, TJ Herzog, BJ Monk, RL ColemanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.